EMERYVILLE, Calif.: EMERYVILLE, Calif., Jan. 3, 2022 /PRNewswire/ — Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, today announced that the company has entered into […]
The latest Healthy Minds Network survey of nearly 104,000 U.S. college students found that nearly half had screened positive for anxiety or depression or both. Click here to view original post
EMERYVILLE, Calif. and CULVER CITY, Calif.: EMERYVILLE, Calif. and CULVER CITY, Calif., Jan. 3, 2022 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market […]
NEW YORK: NEW YORK, Jan. 3, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential […]
SAN DIEGO: SAN DIEGO, Jan. 3, 2022 /PRNewswire/ — Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its […]
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in […]
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva […]
The omicron variant of Covid-19 is upending more Massachusetts colleges’ operations, as an increasing number are changing their intersession or spring semester plans. Click here to view original post
Happy New Year! Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Abbvie is developing a cocktail of drugs to treat people with cystic fibrosis, which if proven […]
Failing to grant a hearing on the Xtandi march-in petitions would signal that the federal government will continue to be a paper tiger when it comes to demonstrably unreasonable drug… Click to view original post
© 2023 Biotech Networks, LLC
